Transcriptional Control of Brown Fat Development  by Kajimura, Shingo et al.
Cell Metabolism
Minireview
Focus on Brown Adipose TissueTranscriptional Control of Brown Fat DevelopmentShingo Kajimura,1,2 Patrick Seale,3 and Bruce M. Spiegelman1,2,*
1Dana-Farber Cancer Institute
2Department of Cell Biology
Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
3Institute for Diabetes, Obesity and Metabolism, University of Pennsylvania School of Medicine, Clinical Research Building (CRB) 727,
415 Curie Boulevard, Philadelphia, PA 19104, USA
*Correspondence: bruce_spiegelman@dfci.harvard.edu
DOI 10.1016/j.cmet.2010.03.005
Deconvoluting the natural pathway of BAT development has defined key molecular events, which enables
researchers to manipulate the amount or activity of brown fat. We review recent advances on the transcrip-
tional regulation of BAT development and discuss the emerging questions.Introduction
In contrast towhite adipose tissue (WAT), which is specialized for
the storage of excess energy, brown adipose tissue (BAT) dissi-
pates chemical energy to produce heat as a defense against
cold. Interest in the development and regulation of BAT has
exploded in the last few years because of a confluence of
discoveries in the biology and physiology of the brown adipo-
cyte. Clearly, much of the interest in this cell type is due to its
role in the defense against hypothermia and obesity. Observa-
tions originally made in the oncology clinic with 18fluoro-labeled
2-deoxyglucose positron emission tomography (18FDG-PET)
scanning have led to an appreciation that most, if not all, adult
humans have distinct brown fat deposits, and the activity of
BAT varies depending on age, adiposity, temperature, and
gender (Cypess et al., 2009; Saito et al., 2009; van Marken Lich-
tenbelt et al., 2009; Virtanen et al., 2009). Furthermore, a major
transcriptional regulator of brown fat cell identity, PRDM16, was
recently discovered. This is the first cell-autonomous transcrip-
tional component that is both necessary and sufficient to stimu-
late the development of brown fat cells. This offers a new oppor-
tunity to investigate the developmental origins of brown fat and
provides a new pathway for the manipulation of BAT in vivo. In
this article, we review the current understanding of the transcrip-
tional regulation and cellular origin of brown fat development.
Transcriptional Regulators of Brown Fat Cell
Development and Differentiation
Despite the differences in the developmental origins and physi-
ological functions of brown andwhite adipocytes, both cell types
share a very similar transcriptional cascade that controls the
process of fat differentiation. Detailed studies of white fat differ-
entiation had previously identified PPARg (peroxisome prolifera-
tor-activated receptor-g) and the C/EBPs (CCAAT/enhancer-
binding proteins) as key transcription factors driving fat cell
differentiation (reviewed in Farmer, 2006). Indeed, PPARg is
absolutely necessary for both white fat and brown fat cell devel-
opment. C/EBPs function cooperatively with PPARg and
promote a transcriptional cascade that promotes and maintains
the stable differentiated state of adipocytes. While C/EBPa is
essential for the normal insulin sensitivity of mature fat cells, it
is required only for the formation of white fat, not brown fat, sug-
gesting a possible role for other C/EBP family members in brownfat development. C/EBPb and d, as well as other transcription
factors, also participate in the transcriptional cascade of adipo-
genesis by regulating PPARg gene expression. Brown fat cell
differentiation requires PPARg but, importantly, this factor alone
is not sufficient to drive mesenchymal cells into a brown fat
program. This led us and other investigators to hunt for transcrip-
tional components that would specifically promote a brown fat
genetic program, including the expression of UCP1. As
described below, several transcriptional factors and cofactors
that affect the expression of UCP1 and that of other key brown
fat-selective genes have been identified.
Forkhead Box C2
Forkhead box C2 (FOXC2) is a member of the forkhead/winged
helix transcription factor family whose gene expression is en-
riched in the adipose tissues of human and mouse. Enerback
and colleagues reported that transgenic expression of FOXC2
in the adipose tissue induced the emergence of brown fat-like
cells in WAT, with increased mitochondria and elevated expres-
sion of thermogenic genes, including UCP1 and PPARg-coacti-
vator-1a (PGC-1a) (Cederberg et al., 2001). Notably, transgenic
expression of FOXC2 counteracts many obesity-associated
pathologies, including insulin resistanceandhypertriglyceridemia
(Cederberg et al., 2001). This ‘‘browning’’ effect stimulated by
FOXC2 seems mainly a result of inducing the expression of the
RIa subunit of cAMP-dependent protein kinase (PKA). This sensi-
tizes cells to cAMP signaling through the b-adrenergic pathway.
PGC-1a and Its Transcriptional Regulators
PGC-1a was originally identified from brown fat cells as a cold-
inducible coactivator of PPARg (Puigserver et al., 1998). Accu-
mulating evidence indicates that PGC-1a is a master regulator
of mitochondrial biogenesis and oxidative metabolism in most
cell types, including brown fat and skeletal muscle. Indeed,
genetic ablation of PGC-1a results in reduced capacity for
cold-induced thermogenesis in vivo and in a blunted response
to cAMP signaling in cultured brown fat cells. Similarly, ectopic
expression of PGC-1a in white fat cells induces a number of
mitochondrial genes and thermogenic genes, such as Ucp1
(Puigserver et al., 1998).
Several transcriptional regulators have been shown to control
brown fat development and function, at least in part, through
regulating the transcriptional activity or gene expression of
PGC-1a. RIP140, a corepressor of many nuclear receptors,Cell Metabolism 11, April 7, 2010 ª2010 Elsevier Inc. 257
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1a through a physical interaction (Hallberg et al., 2008). Genetic
ablation of RIP140 causes the emergence of brown fat-like cells
in WAT (Leonardsson et al., 2004). Similarly, SRC2/TIF2/GRIP1,
a member of the steroid receptor coactivator (SRC) family,
represses PGC-1a transcriptional activity. Loss of SRC2 func-
tion leads to an increase in adaptive thermogenesis and energy
expenditure in vivo (Picard et al., 2002). Rb (retinoblastoma)
protein and p107, another member of the Rb pocket protein
family, also negatively regulate PGC-1a gene expression. Adipo-
cytes derived from pRb-deficient fibroblasts or embryonic stem
cells exhibit a brown fat phenotype with high mitochondrial
content and elevated expression of UCP1, PGC-1a, and mito-
chondrial genes (Hansen et al., 2004). p107-deficient mice
display a striking accumulation of brown fat-like cells in WAT,
with multilocular lipid droplets, abundant mitochondria, and
high levels of UCP1 and PGC-1a expression (Scime` et al.,
2005). The biological effect of p107 on brown fat development
appears to be mediated through the repression of pRb, because
pRb levels are significantly reduced in Sca-1+ CD31 Lin adipo-
genic precursors isolated from p107-deficient mice. Lastly,
TWIST1, a helix-loop-helix-containing transcriptional regulator,
has recently been reported as a negative regulator of PGC-1a
function in brown fat. Genetic ablation or depletion of TWIST1
induces the expression of brown fat-selective genes, while over-
expression of TWIST1 represses them in a PGC-1a-dependent
fashion (Pan et al., 2009).
Taken together, these data suggest a dominant role for
PGC-1a in brown fat development and its thermogenic function.
However, the mass of BAT and the expression of many brown
fat-selective genes are not affected by the depletion of
PGC-1a. Thus, while PGC-1a is a crucial regulator of adaptive
thermogenesis and mitochondrial biogenesis, it does not deter-
mine the cellular specification of brown fat.
PRD1-BF-1-RIZ1 Homologous Domain Containing
Protein-16
PRD1-BF-1-RIZ1 homologous domain containing protein-16
(PRDM16) is a 140 kDa zinc finger protein thatwasoriginally iden-
tified at a chromosomal breakpoint of t(1;3)(p36;q21)-positive
human acute myeloid leukemia cells (Mochizuki et al., 2000).
Our previous study showed that PRDM16 expression was highly
enriched in BAT compared with WAT (Seale et al., 2007). When
ectopically expressed in white fat preadipocytes or myoblasts,
PRDM16 induces a nearly complete brown fat genetic program.
This includes mitochondrial biogenesis, increased cellular respi-
ration, and expression of brown fat-selective genes, both the
cAMP-inducible thermogenic genes (Ucp1, Pgc-1a, and Deiodi-
nase-d2) and those BAT-selective genes that are not sensitive to
cAMP (such as Cidea and Elovl3). Furthermore, transgenic
expression of PRDM16 in adipose tissue increases the formation
of pockets of multilocular brown-like adipocytes in WAT depots
under stimulation with a b-adrenergic agonist.
PRDM16 had previously been shown to bind directly to
a specific DNA sequence via two sets of zinc fingers (ZF1 and
ZF2 domains) in vitro. Interestingly, abrogation of DNA binding
using a point mutation did not substantially alter the ability of
PRDM16 to induce the brown fat phenotype when compared
to the wild-type protein. This suggested that PRDM16 was not
working as a classical DNA-binding transcription factor. Further258 Cell Metabolism 11, April 7, 2010 ª2010 Elsevier Inc.study demonstrated that, in addition to inducing the gene
expression of PGC-1a, PRDM16 directly binds to both PGC-1a
and PGC-1b to increase their transcriptional activities (Seale
et al., 2007). These results directed us to search for other binding
partners that further specified the actions of PRDM16. In fact,
PRDM16 interacts with a variety of canonical DNA-binding tran-
scription factors, such as PPARa, PPARg, p53, and several
members of the C/EBP family (Kajimura et al., 2009; Seale
et al., 2008). In each case, binding is via one or more of
PRDM16’s zinc finger domains, resulting in powerful coactiva-
tion of their transcriptional activities (Figure 1A). On the other
hand,PRDM16expression inwhite fat precursors or inmyoblasts
robustly repressesgeneexpressionof selectivemarkers forwhite
fat cells or skeletal muscle, respectively. The repressive effect of
PRDM16 onwhite fat cell-selective genes ismediated through its
regulated association with C-terminal binding proteins (CtBP1
and 2), well-known corepressor proteins (Kajimura et al., 2008).
These results indicate that PRDM16 is a coregulatory protein
that can function as a bidirectional switch in brown fat develop-
ment through multiple protein-protein interactions.
Depletion of PRDM16 in primary brown fat cell precursors not
only causes a near-total loss of brown fat characteristics but
also, unexpectedly, causes the emergence of distinct morpho-
logical and genetic characteristics of skeletal myotubes in
culture. These include the formation of syncytia and ectopic acti-
vation of skeletal muscle-specific genes. Consistent with this,
BAT from PRDM16-deficient mice exhibits an abnormal
morphology, with reduced expression of brown fat-selective
marker genes and elevated expression of skeletal muscle-
specific genes (Seale et al., 2008). Conversely, expression of
PRDM16 in myogenic precursors drives a robust and functional
program of brown adipogenesis. These results suggest that
PRDM16 is a critical determinant of the brown fat lineage from
myoblast progenitors during the embryonic development.
How does PRDM16 control the conversion of myoblastic
precursors to brown fat? Recent studies from our group demon-
strated that PRDM16 forms a transcriptional complex with the
active form of C/EBPb (LAP) that is abundantly expressed both
in brown fat and myoblasts (Kajimura et al., 2009). It has also
been reported that C/EBPb is a dominant transcription factor
that controls cAMP-induced gene expression in brown fat cells
(Karamitri et al., 2009). Indeed, depletion of C/EBPb significantly
blunts the ability of PRDM16 to induce the brown fat differentia-
tion and specific fat gene program in myoblasts. Consistent with
this finding, BAT from C/EBPb-deficient mice displays a similar
molecular signature to BAT from PRDM16-deficient mice, with
reduced expression of BAT-selective genes and elevated
expression of skeletal muscle-selective genes. These studies
indicate that a PRDM16-C/EBPb complex controls the initiating
events of the conversion from myoblastic precursors to brown
fat cells (Figure 1B).
Surprisingly, the combination of these two factors (PRDM16
and C/EBPb) is sufficient to induce a fully functional brown fat
program in nonadipogenic cells such as embryonic fibroblasts
and skin fibroblasts from mouse and man. Cells expressing
these two factors differentiate into mature adipocytes with
extremely high oxygen consumption and high expression of
brown fat-selective genes, including Ucp1 and Pgc-1a. Further-
more, when transplanted into immunocompromised mice,
Figure 1. Transcriptional Control of Brown Fat Development
through PRDM16
(A) Structure of PRDM16 and key domains of its function. PRDM16 directly
interacts with canonical transcription factors such as PPARa, PPARg, and
C/EBP family members and transcriptional coactivators PGC-1a and PGC-
1b through the two sets of zinc finger domains (ZF1 and ZF2). PRDM16 is
also associated with the corepressors CtBP1 and 2 through its PLDLS motif.
This interaction mediates the repressive action of PRDM16 on the expression
of white fat cell-specific genes.
(B) PRDM16-C/EBPb transcriptional complex acts inMyf5-positivemyoblastic
precursors or preadipocytes to induce the expression of PPARg and PGC-1a.
PRDM16 coactivates PPARg and PGC-1a, which then drives a brown fat
differentiation program. The cAMP-dependent thermogenic gene program is
potentiated by FOXC2 and PRDM16. RIP140, Rb/p107, and TWIST1 antago-
nize the expression or transcriptional activity of PGC-1a and repress brown fat
genetic program.
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fat pad that displays a brown fat-like phenotype: multilocular
adipocytes expressing UCP1. Importantly, similar to endoge-
nous BAT, this engineered brown fat tissue can function as
a sink for active glucose disposal, as determined by FDG-PET
scanning (Kajimura et al., 2009).Developmental Origin of Brown Fat
Because WAT and BAT share many common features, including
a conserved PPARg-driven transcriptional programof adipogen-
esis, these tissues have been assumed to share a direct
common progenitor. However, recent studies indicate that
brown adipocytes are developmentally closer to skeletal muscle
than to white adipose cells (Figure 2). In particular, genetic fate-
mapping experiments indicate that BAT in the interscapular
region and skeletal muscle but not white adipose cells arise
from cells that express Myf5, a gene previously assumed to be
present almost exclusively in committed skeletal muscle precur-
sors (Seale et al., 2008). Similarly, Engrailed-1 (En1)-expressing
cells in the central dermomyotome form BAT, skeletal muscle,
and dermis (Atit et al., 2006). Whether En1-expressing cells
give rise to anywhite adipose lineageswasnot examined. In addi-
tion, global gene expression analyses by the Cannon and Neder-
gaard group show that brown but not white adipocyte precursors
express a gene profile related to that of skeletal muscle cells
(Timmons et al., 2007). Most recently, the mitochondrial proteo-
mic signature of BAT was shown to be highly related to that of
skeletal muscle but not to that of WAT (Forner et al., 2009).
As described above, PRDM16 appears to function as a major
determinant of a brown adipose/skeletal muscle fate switch from
a common cellular precursor compartment. Interestingly,
genetic ablation of PRDM16 in mouse caused a significant but
relatively modest reduction in the molecular and morphological
characteristics of brown fat (Seale et al., 2008). This suggests
a parallel or independent pathway or pathways that direct
a subset of myoblasts into brown adipocyte lineage in vivo.
There are 17 members of PRDM16 family in mammals, and it is
possible that one of more of these may compensate for the
chronic loss of PRDM16 during embryogenesis. Notably, myo-
genin-deficient mice that completely lack differentiated skeletal
muscle have an expanded BAT depot in the interscapular
region. Together, these findings are consistent with the hypoth-
esis that BAT shares a direct common upstream precursor with
skeletal muscle cells. It will now be important to examine
whether Myf5-expressing cells can clonally give rise to both
cell lineages.
The signaling molecules that control the timing and specificity
of PRDM16 expression and commitment to the brown adipose
lineage are unknown. Bone morphogenic proteins (BMPs),
members of the TGF-b superfamily of secreted factors, have
been suggested to facilitate adipogenic differentiation. Of partic-
ular interest is BMP7, which has been described as a selective
and potent inducer of brown but not white adipogenesis in prea-
dipocyte and multipotent fibroblast cultures (Tseng et al., 2008).
BMP7 treatment of fibroblast cultures is associated with induc-
tion of key brown adipogenic regulators such as PRDM16 and
PGC-1a, although the mechanisms that mediate this effect are
not known. Importantly,BMP7-deficient embryospossesssignif-
icantly reduced amounts of BAT that lack UCP1 expression. The
cellular specificity and timing of BMP7 signaling in BAT is an
important open question for future experiments. Interestingly,
certain BMPs also negatively regulate skeletal myogenesis, sug-
gesting that BMP7 or a related family member may act on early
somitic precursor cells to direct brown adipocyte versus skeletal
muscle cell determination. Another member of the TGF-b
superfamily, GDF-3, has been shown to negatively regulate aCell Metabolism 11, April 7, 2010 ª2010 Elsevier Inc. 259
Figure 2. Hierarchical Developmental Relationships in Adipose
(A) BAT (A) and WAT (B) have separate developmental origins in the embryo. BAT and skeletal muscle originate from precursors in the dermomyotome that
express Engrailed-1 (En1) and Myf5. Brown adipose fate in the somite may be controlled by members of the transforming growth factor (TGF)-b superfamily
of secreted factors, such as BMP7. Canonical Wnt signaling represses the differentiation of brown preadipocytes into mature brown adipose cells. PRDM16,
PPARg, PGC-1a, and UCP1 are functional markers of brown adipose cells in the developmental, homogenous deposits of BAT. MyoD expression and skeletal
muscle commitment are positively regulated by Wnt, Sonic Hedgehog (Shh), and Noggin. BMPs suppress myogenic commitment.
(B) The embryonic stem cells of the white adipose lineage remain to be well defined. White preadipocytes that express PPARg differentiate into mature white
adipose cells in a process that also appears to be stimulated by certain BMPs. The adaptive Ucp1-expressing brown-like adipose cells that develop in WAT
in response to cold or b-adrenergic stimulation are not descendent fromMyf5-expressing cells. These cells may be derived from (1) a specialized compartment
ofMyf5-negative but committed brown precursors, (2) directed differentiation from white preadipocytes, and/or (3) transdifferentiation from mature white adipo-
cytes (as indicated). The broken arrows depict hypothetical precursor-product relationships.
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could also play a role in BAT development (Shen et al., 2009).
Activation of the canonicalWingless (Wnt) signaling pathway is
also associated with opposing effects on adipose and skeletal260 Cell Metabolism 11, April 7, 2010 ª2010 Elsevier Inc.muscle lineages. Specifically, Wnt activation represses both
brown and white adipogenesis by suppressing the induction of
PPARg and C/EBPa in precursor cells (Ross et al., 2000). By
contrast, Wnt ligands are crucial inductive cues for embryonic
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tion factors. Fibroblast growth factors (FGFs) 16, 19 (FGF15
in mouse), and 21 have also been implicated in the regulation
of brown adipogenesis and thermogenic activity of brown fat
(Konishi et al., 2000).
In addition to the dedicated depots of brown adipocytes that
are formed before birth, ‘‘brown adipocyte-like’’ cells are also
found interspersed in WATs of adult animals that have been
acclimated to cold or chronically treated with selective b3-
adrenergic agonists. These induced ‘‘brown adipocyte-like’’
cells express UCP1 and have a multilocular morphology similar
to their counterparts in preformed depots. However, these cells
have a distinct developmental origin, since they are not descen-
dent from a Myf5-expressing progenitor (Seale et al., 2008). It
thus remains to be determined whether mature white adipose
cells, committed populations of preadipocytes, or undetermined
stem cells are the source of these brown fat-like cells. Strain-
dependent variability in the expression of UCP1 in brown
adipose cells from retroperitoneal WAT but not in those from in-
terscapular BAT depots suggests that these cell types are genet-
ically dissimilar (Xue et al., 2007). The developmental origins and
molecular characteristics of these cells will be very important to
understand. While the supraclavicular depots of brown fat in hu-
mans form distinct pads in a predictable location and are thus
likely analogous to the BAT arising from muscle in mice, brown
fat cells interspersed in white depots are also found in humans.
Emerging Questions and Therapeutic Opportunities
Recent advances in brown fat biology and physiology further
suggest its pivotal role in controlling energy homeostasis and
its promise as a therapeutic approach to combat obesity in
mice and humans. For example, a number of studies in animal
models (e.g., fat-selectiveUcp1 transgenicmouse) have demon-
strated that increases in amount or activity of brown fat can coun-
teract obesity through increasing whole-body energy expendi-
ture. The new findings on the regulation of brown fat
development have identified key cellular and molecular events,
as reviewedabove,whichnowenable researchers to aska variety
of fundamental questions in the field. For example, how much
brown fat is needed to alter whole-body energy expenditure
and counteract obesity? This can be determined either by trans-
plantation of brown fat cells or with transgenic animal models.
Since skin fibroblasts or the stromal vascular fraction from
adipose tissues are relatively easy to obtain, even from humans,
autologous transplantation of engineered brown fat cells gener-
ated by expressing PRDM16 and C/EBPb would be a feasible
way to explore this question. It is also extremely important to
clarify, via key transcriptional regulators such as FOXC2, pRb,
RIP140, PRDM16, and PGC-1a, if there is a single, unified
pathway/mechanism(s) acting to induce brown fat development.
Betterunderstandingof themolecular circuits that regulatebrown
fat specification and development will lead to identification of
novel and specific pharmacological targets for antiobesity drugs.
One of the major unsolved questions is the molecular identity
and cellular origins of the cAMP-inducible ‘‘brown fat-like’’ cells
residing in the WAT. As described above, it does seem clear that
a cAMP-induced transformation of WAT to BAT, presumably
from a Myf5-independent cell lineage, is associated with
a protection against obesity and metabolic diseases (Cederberget al., 2001; Leonardsson et al., 2004). Identifying specific cell
surface markers and establishing methods to isolate this cell
population will advance our understanding of this issue. In addi-
tion, the role of BAT developmental regulators such as PRDM16
and PGC-1a in the formation of cAMP-induced ‘‘brown fat-like’’
cells and metabolic benefit must now be assessed.
Since gene transfer or cellular transplantation may not be an
optimal method for human therapeutics in the metabolic
syndrome, we also need to explore alternative ways to induce
brown fat activity and development. Screening chemical
compounds or drugs to induce dominant brown fat regulators
such as PRDM16, FOXC2, or PGC-1a is certainly plausible.
Alternatively, characterizing the upstream inductive compo-
nents, such as endogenous hormones/polypeptides that stimu-
late the formation of brown fat cells during development, will be
valuable. Likewise, new drugs or polypeptides that increase
differentiation or activity of BAT that exists in adult humans
may offer new treatments for obesity and diabetes.ACKNOWLEDGMENTS
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